Elisabeth Leiderman
Director/Board Member bei BLUEBIRD BIO, INC.
Vermögen: 28 488 $ am 31.03.2024
Profil
Elisabeth Leiderman is an Independent Director at bluebird bio, Inc. and a Non-Executive Director at Autolus Therapeutics Plc.
She previously worked as an Executive Director at Nomura Securities, Inc., VP-Business & Corporate Development at Fortress Biotech, Inc., Chief Business Officer at Complexa, Inc., Chief Financial & Accounting Officer at Decibel Therapeutics, Inc., and Chief Financial & Business Officer at Atsena Therapeutics, Inc. Dr. Leiderman holds an undergraduate degree from the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from Sackler School of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
BLUEBIRD BIO, INC.
0,01% | 16.06.2023 | 22 256 ( 0,01% ) | 28 488 $ | 31.03.2024 |
Aktive Positionen von Elisabeth Leiderman
| Unternehmen | Position | Beginn |
|---|---|---|
| BLUEBIRD BIO, INC. | Director/Board Member | 15.10.2021 |
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 20.12.2023 |
Ehemalige bekannte Positionen von Elisabeth Leiderman
| Unternehmen | Position | Ende |
|---|---|---|
Atsena Therapeutics, Inc.
 Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Director of Finance/CFO | 01.11.2023 |
| DECIBEL THERAPEUTICS, INC. | Director of Finance/CFO | 07.10.2022 |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Corporate Officer/Principal | 01.08.2020 |
| Nomura Securities, Inc. | Director/Board Member | 01.07.2016 |
| FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 01.01.2016 |
Ausbildung von Elisabeth Leiderman
| University of Pennsylvania | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Sackler School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| FORTRESS BIOTECH, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Health Technology |
| Nomura Securities, Inc. |
